Status:
COMPLETED
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
Lead Sponsor:
Intarcia Therapeutics
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
40+ years
Phase:
PHASE3
Brief Summary
Phase 3 study to Evaluate cardiovascular outcomes in patients with type 2 diabetes treated with ITCA 650.
Eligibility Criteria
Inclusion
- HBA1c \> 6.5%
- History of coronary, cerebrovascular or peripheral artery disease
Exclusion
- history of pancreatitis
Key Trial Info
Start Date :
March 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2016
Estimated Enrollment :
4156 Patients enrolled
Trial Details
Trial ID
NCT01455896
Start Date
March 1 2013
End Date
March 1 2016
Last Update
January 27 2017
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Study Site
Chandler, Arizona, United States, 85224
2
Intarcia Therapeutics, Inc
Hayward, California, United States, 94545
3
Study Site
Long Beach, California, United States, 90806
4
Study Site
Port Hueneme, California, United States, 93041